Evvy Expands Market-Leading Vaginal Health Test with First-of-its-Kind Fertility Insights

The Leader in Vaginal Microbiome Testing Launches Novel Fertility Insights to Help Individuals Promote Reproductive Health

NEW YORK--(BUSINESS WIRE)--Evvy, the company closing the gender health gap through biomarkers in the vaginal microbiome, is introducing groundbreaking Fertility Insights within its flagship Vaginal Microbiome Test. As the first and only validated, at-home, mNGS vaginal microbiome test, Evvy is now expanding its capabilities to provide science-backed insights on the role of the vaginal microbiome in fertility.

The vaginal microbiome is the community of bacteria, fungi, and viruses that live in the vagina — and emerging research highlights its crucial role in reproductive health. An imbalance in the vaginal microbiome can increase inflammation and the risk of infection in the reproductive tract, creating a less hospitable environment for conception. On the other hand, a microbiome dominated by protective bacteria, such as Lactobacillus crispatus, has been associated with improved fertility, successful implantation, and improved pregnancy outcomes.

Today, one-third of all infertility cases are diagnosed as “unexplained.” While research has long linked vaginal microbial imbalances to infertility, recurrent pregnancy loss, and preterm birth, in-depth vaginal microbiome testing had not been widely accessible — until now. Evvy is closing this gap by providing first-of-its-kind, fertility-specific insights to help individuals understand and optimize this crucial but often overlooked aspect of their reproductive health.

“The connection between the vaginal microbiome and fertility is one of the most exciting frontiers in reproductive health,” said Dr. Kate McLean, Chief Medical Officer at Evvy. “We’ve seen compelling research linking specific vaginal bacteria to everything from embryo implantation to pregnancy loss — yet this crucial information wasn’t available to patients or providers in fertility care. By making these insights accessible, Evvy is bridging the gap between cutting-edge science and real-world clinical impact, giving individuals and providers a new tool to support reproductive success.”

How Evvy’s New Fertility Insights Work

Evvy’s world-leading science and clinical teams combined findings from the latest research with insights from Evvy’s extensive dataset to identify the key microbial signatures linked to fertility outcomes — and created new insights to highlight these associations. Evvy’s test result experience now includes a new section for these Fertility Insights:

• Protective Score: A measure of the levels of protective bacteria that are associated with positive outcomes. Higher levels of protective bacteria like Lactobacillus — especially Lactobacillus crispatus — are associated with improved fertility, lower inflammation, and better pregnancy outcomes.
• Microbiome Diversity Score: A measure of overall microbiome diversity. Higher microbiome diversity has been linked to poorer IVF and pregnancy outcomes.
• Fertility Disruptors: Levels of bacteria specifically associated with negative fertility outcomes, including Fannyhessea, Gardnerella, and Prevotella.
• STI Testing (add-on): Evvy’s STI + PCR test panel screens for sexually transmitted infections, which are directly linked to infertility and pregnancy complications. If an STI is detected, users can access treatment through Evvy’s platform.

For each insight, Evvy highlights where your results fall on the optimal ranges for fertility based on the latest research. In addition to the insights, Evvy provides access to their innovative and effective care protocols to optimize the vaginal microbiome through personalized prescription treatments, lifestyle recommendations, and 1:1 health coaching. An upcoming publication (currently under review) showcases the power of Evvy’s care platform in driving measurable improvements in the vaginal microbiome, including the markers that underlie Evvy’s new Fertility Insights.

“For too long, fertility has been treated like a black box — leaving millions of people searching for answers with no clear path forward,” said Priyanka Jain, co-founder and CEO of Evvy. “By expanding our Vaginal Microbiome Test to include fertility insights, we’re giving people the power to take control of their reproductive health with comprehensive testing and data-driven, personalized care.”

Through Evvy’s test and care platform, users can actively test and improve their microbiome health before trying to conceive, undergoing IVF (which on average costs $12,000 - $25,000), or addressing unexplained infertility concerns. Evvy's Vaginal Microbiome Test is already available in all 50 states, starting at $129 at Evvy.com. Users who purchase a Vaginal Microbiome Test after March 18th will have Fertility Insights included automatically in their test results.

About Evvy

Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy’s groundbreaking Vaginal Health Test is the world’s only certified, peer-reviewed vaginal microbiome test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways and 1-1 coaching, Evvy provides over 50,000 women with data-driven, personalized healthcare for vaginal infections, fertility, menopause, and more. Evvy has built the world’s largest dataset on the vaginal microbiome, and they are pioneering novel research to transform female health outcomes.